Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway (Q39170232)

9 September 2017

Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway (English)

1 reference

9 September 2017

0 references

hepatocellular carcinoma

1 reference

Ai-Mei Gao

1

1 reference

9 September 2017

Zun-Ping Ke

2

1 reference

9 September 2017

Jia-Ning Wang

3

1 reference

9 September 2017

Jian-Ye Yang

4

1 reference

9 September 2017

Shi-You Chen

5

1 reference

9 September 2017

Hui Chen

6

1 reference

9 September 2017

language of work or name

English

0 references

publication date

4 April 2013

1 reference

9 September 2017

1 reference

9 September 2017

34

1 reference

9 September 2017

1806-1814

1 reference

9 September 2017

8

1 reference

Hepatocellular carcinoma: A global view.

9 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

Inhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

Discovery of the negative regulator of Nrf2, Keap1: a historical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

A new model for raf kinase inhibitory protein induced chemotherapeutic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

Nuclear factor (erythroid-derived 2)-like 2 regulates drug resistance in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

Regulation of aldo-keto reductase AKR1B10 gene expression: involvement of transcription factor Nrf2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

Epidermal growth factor induces tumour marker AKR1B10 expression through activator protein-1 signalling in hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

Apoptotic effects of genistein, biochanin-A and apigenin on LNCaP and PC-3 cells by p21 through transcriptional inhibition of polo-like kinase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

Protection by chrysin, apigenin, and luteolin against oxidative stress is mediated by the Nrf2-dependent up-regulation of heme oxygenase 1 and glutamate cysteine ligase in rat primary hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

NRF2 and cancer: the good, the bad and the importance of context.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT108

21 January 2018

Identifiers

DOI

10.1093/CARCIN/BGT108

1 reference

9 September 2017

1 reference